Fatal cases of chronic hepatitis delta: clinical, biochemical and virological characteristics
- Authors: Isaeva O.V.1,2, Kyuregyan K.K.1,2, Ilchenko L.Y.2,3,4, Karlsen A.A.1,2, Asadi Mobarkhan F.A.2, Saryglar A.A.5, Mikhailov M.I.1,2
-
Affiliations:
- Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of Russia
- I.I. Mechnikov Research Institute of Vaccines and Sera
- M.P. Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences
- N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia
- Infectious Diseases Hospital
- Issue: Vol 7, No 4 (2021)
- Pages: 48-56
- Section: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/288198
- DOI: https://doi.org/10.18565/therapy.2021.4.48-56
- ID: 288198
Cite item
Abstract
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
Olga V. Isaeva
Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of Russia; I.I. Mechnikov Research Institute of Vaccines and Sera
Email: isaeva.06@mail.ru
candidate of biological sciences, leading researcher of Research Institute of Molecular and Personalized Medicine; leading researcher of Laboratory of viral hepatitis 125284, Moscow, 7/2 Botkinsky pr. Str
Karen K. Kyuregyan
Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of Russia; I.I. Mechnikov Research Institute of Vaccines and SeraDoctor of biological sciences, professor of RAS, Chief researcher, head of the Department of socially significant viral infections, Research Institute of Molecular and Personalized Medicine; leading researcher of Laboratory of viral hepatitis 125284, Moscow, 7/2 Botkinsky pr. Str; 125284, Moscow, 7/2 Botkinsky pr. Str
Lyudmila Yu. Ilchenko
I.I. Mechnikov Research Institute of Vaccines and Sera; M.P. Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences; N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of RussiaMD, professor, professor of the Department of hospital therapy No. 2 of the Faculty of medicine; leading researcher of Laboratory of modeling immunobiological processes at the experimental clinic of marmoset monkeys; leading researcher of Laboratory of viral hepatitis 115516, Moscow, 26 Bakinskaya Str
Anastasia A. Karlsen
Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of Russia; I.I. Mechnikov Research Institute of Vaccines and Seraresearcher of Research Institute of Molecular and Personalized Medicine; researcher of Laboratory of viral hepatitis 125284, Moscow, 7/2 Botkinsky pr. Str
Fyodor A. Asadi Mobarkhan
I.I. Mechnikov Research Institute of Vaccines and Seraresearcher of Laboratory of viral hepatitis 105064, Moscow, 5A Maly Kazyonny Lane
Anna A. Saryglar
Infectious Diseases Hospital
Email: infeksiatuva@mail.ru
PhD, Chief physician 667003, Kyzyl, 65 Chekhova Str
Mikhail I. Mikhailov
Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of Russia; I.I. Mechnikov Research Institute of Vaccines and SeraMD, corresponding member of RAS, head of Laboratory of viral hepatitis; Scientific Director of Research Institute of Molecular and Personalized Medicine 105064, Moscow, 5A Maly Kazyonny Lane
References
- Rizzetto M. Hepatitis D virus: introduction and epidemiology. In: Seeger C., Locarnini S., eds. The hepatitis B and Delta viruses. Cold Spring Harbor perspectives in medicine. Cold Spring Harbor Laboratory Press. New York. 2015; 305-13.
- Rizzetto M., Hamid S., Negro F. The changing context of hepatitis D. J Hepatol. 2021: S0168-8278(21)00023-4. doi: 10.1016/j.jhep.2021.01.014.
- Koh C., Da B.L., Glenn J.S. HBV/HDV coinfection: a challenge for therapeutics. Clin Liver Dis. 2019; 23(3): 557-72. doi: 10.1016/j. cld.2019.04.005.
- Wedemeyer H., Hardtke S., Manns M. Treatment of hepatitis delta. Clin Liver Dis (Hoboken). 2013; 2(6): 237-39. doi: 10.1002/cld.254.
- Mentha N., Clement S., Negro F., Alfaiate D. A review on hepatitis D: from virology to new therapies. J Adv Res. 2019; 17: 3-15. doi: 10.1016/j.jare.2019.03.009.
- Heller T., Rotman Y., Koh C. et al. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther. 2014; 40(1): 93-104. doi: 10.1111/apt.127880.
- Wedemeyer H., Yurdaydin C., Hardtke S. et al. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis. 2019; 19(3): 275-86. doi: 10.1016/S1473-3099(18)30663-7.
- Bogomolov P., Alexandrov A., Voronkova N. et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J Hepatol. 2016; 65(3): 490-98. doi: 10.1016/j.jhep.2016.04.016.
- Wedemeyer H., Bogomolov P., Blank A. et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection. J Hepatol. 2018; 68(1): S3. doi: 10.1016/S0168-8278(18)30224-1.
- Klushkina V.V., Kyuregyan K.K., Kozhanova T.V. et al. Impact of universal hepatitis B vaccination on prevalence, infection-associated morbidity and mortality, and circulation of immune escape variants in Russia. PLoS One. 2016; 11(6): e0157161. doi: 10.1371/journal.pone.0157161.
- Исаева О.В., Ильченко Л.Ю., Сарыглар А.А. с соавт. Течение и исходы хронического вирусного гепатита D у жителей Республики Тыва как эндемичного региона. Вопросы вирусологии. 2021; 1: 74-83. doi: https://doi.org/10.36233/0507-4088-29.
- Ильченко Л.Ю., Кожанова Т.В., Кюрегян К.К. с соавт. Развитие гепатоцеллюлярной карциномы в исходе хронической дельтаинфекции. Архивъ внутренней медицины. 2014; 4: 57-63. doi: https://doi.org/10.20514/2226-6704-2014-0-4-57-63.
- Безуглова Л.В., Мануйлов В.А., Осипова Л.П. с соавт. Результаты испытаний реагентов для иммуноферментного определения субтипа HBsAg и генотипа вируса гепатита B в образцах плазмы крови человека. Молекулярная генетика, микробиология и вирусология. 2020; 4: 188-195. doi: https://doi.org/10.17116/molgen202038041188.
- Безуглова Л.В., Исаева О.В., Карлсен А.А. с соавт. Генотипы вируса гепатита В, определенные в образцах плазмы крови жителей республики САХА (Якутия) с помощью панели моноклональных антител собственной разработки. Тезисы XXV Всероссийской научно-практической конференции, Лабораторная служба. 2020; 9(1): 14.
- Abbas Z., Qureshi M., Hamid S., Jafri W. Hepatocellular carcinoma in hepatitis D: does it differ from hepatitis B monoinfection? Saudi J Gastroenterol. 2012; 18(1): 18-22. doi: 10.4103/1319-3767.91731.
- Abbas Z., Abbas M., Abbas S., Shazi L. Hepatitis D and hepatocellular carcinoma. World J Hepatol. 2015; 7(5): 777-86. doi: 10.4254/ wjh.v7.i5.777.
- Cross T.J.S., Rizzi P., Horner M. et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol. 2008; 80(2): 277-82. doi: 10.1002/jmv.21078.
- Bockmann J.-H., Grube M., Hamed V. et al. High rates of cirrhosis and severe clinical events in patients with HBV/HDVco-infection: longitudinal analysis of a German cohort. BMC Gastroenterol. 2020; 20(1): 24. doi: 10.1186/s12876-020-1168-9.
- Ji J., Sundquist K., Sundquist J. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. J Natl Cancer Inst.2012; 104(10): 790-92. doi: 10.1093/jnci/djs168.
- Fattovich G., Giustina G., Christensen E. et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European concerted action on viral hepatitis (Eurohep). Gut. 2000; 46(3): 420-26. doi: 10.1136/gut.46.3.420.
- Freitas N., Salisse J., Cunha C. et al. Hepatitis delta virus infects the cells of hepadnavirus-induced hepatocellular carcinoma in woodchucks. Hepatology. 2012; 56(1): 76-85. doi: 10.1002/hep.25663.
- Ricco G., Popa D.C., Cavallone D. et al. Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection. J Viral Hepat. 2018; 25(8): 911-19. doi: 10.1111/jvh.12895.
- Kabacam G., Wedemeyer H., Savas B. et al. HIDIT-1 Study Group. Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. Liver Int. 2014; 34(8): 1207-15. doi: 10.1111/liv.12376.
- Roulot D., Brichler S., Layese R. et al. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis Delta. J Hepatol. 2020; 73(5): 1046-62. doi: 10.1016/j.jhep.2020.06.038.
- Kamal H., Westman G., Falconer K. et al. Long-term study of hepatitis D infection at secondary care centers: the impact of viremia on liver-related outcomes. Hepatology. 2020; 72(4): 1177-90. doi: 10.1002/hep.31214.
- Heidrich B., Serrano B.C., Idilman R. et al. HBeAg-positive hepatitis delta: Virological patterns and clinical long-term outcome. Liver Int. 2012; 32(9): 1415-25. doi: 10.1111/j.1478-3231.2012.02831.
- Chan H. L.-Y., Wong M. L., Hui A. Y. et al. Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients. J Clin Microbiol. 2003; 41(3): 1277-79. doi: 10.1128/jcm.41.3.1277-1279.2003.
- Guedj J., Rotman Y., Cotler S.J. et al. Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology. 2014; 60(6): 1902-10. doi: 10.1002/hep.27357.
- Wu S., Zhang Y., Tang Y. et al. Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with elevated transaminases in Shanghai, China. BMC Infect Dis. 2020; 20(1): 565. doi: 10.1186/s12879-020-05275-1.
- Ильченко Л.Ю., Кожанова Т.В., Сарыглар А.А. с соавт. Клиническое течение и исходы хронической дельта-инфекции в эндемичном регионе. Архивъ внутренней медицины. 2012; 5: 51-56. doi: https://doi.org/10.20514/2226-6704-2012-0-5-51-56.
- Heidrich B., Yurdaydin C., Kabacam G. et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014; 60(1): 87-97.’ doi: 10.1002/hep.27102.
- Yurdaydin C. Treatment of chronic delta hepatitis. Semin Liver Dis. 2012; 32(3): 237-44. doi: 10.1055/s-0032-1323629.
Supplementary files
![](/img/style/loading.gif)